AstraZeneca forecast to post $14.94 billion Q1 revenue and $2.54 core EPS
Updated
Updated · MarketWatch · Apr 27
AstraZeneca forecast to post $14.94 billion Q1 revenue and $2.54 core EPS
10 articles · Updated · MarketWatch · Apr 27
Analysts expect AstraZeneca’s first-quarter revenue to rise from $13.59 billion last year, with oncology drugs driving growth despite Farxiga inventory reductions.
Shares rose 6.5% in Q1, and analysts believe the company may beat revenue forecasts and reiterate its full-year guidance.
AstraZeneca targets $80 billion revenue by 2030, with recent positive late-stage study results strengthening its long-term outlook and investor focus on new drug candidates.
How will AstraZeneca's $80 billion ambition survive growing global drug pricing pressures?
Why does the market bet against AstraZeneca's new breast cancer drug despite positive trial data?
Can AstraZeneca's new COPD drug tozorakimab truly disrupt the market and reach $5 billion in sales?
Will AstraZeneca's oral obesity pill prove competitive against the popular injectable treatments already on the market?
Is AstraZeneca's late entry into the crowded obesity drug market a strategic blunder or a masterstroke?
How will AstraZeneca's massive China investment navigate increasing geopolitical and trade tensions?